Litcius/Paper detail

Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study

Tanya Jindal, Cindy Jiang, Omar Alhalabi, Charles B. Nguyen, Eugene Oh, Irene Tsung, Dimitra Rafailia Bakaloudi, Rafee Talukder, Matthew P. Davidsohn, Dory Freeman, Ilana Epstein, Chien‐Kuang Cornelia Ding, Amanda Nizam, Michael Glover, Ali Raza Khaki, Amy K. Taylor, Emily Lemke, Albert Jang, Sean T. Evans, Dongjun Shin, Cameron Pywell, Arnab Basu, Mehmet Asım Bilen, Yousef Zakharia, Pedro Barata, Matthew I. Milowsky, Jason R. Brown, Deepak Kilari, Hamid Emamekhoo, Christopher Hoimes, Sumit Shah, Nancy B. Davis, Shilpa Gupta, Petros Grivas, Joaquim Bellmunt, Ajjai Alva, Matthew T. Campbell, Vadim S. Koshkin

2025European Urology10 citationsDOI

Topics & Concepts

MedicineInternal medicineOncologyUrothelial cancerMEDLINEClinical trialNeoplasm stagingPathologyChemotherapyNephrologyBladder and Urothelial Cancer TreatmentsEsophageal Cancer Research and TreatmentCancer, Lipids, and Metabolism
Outcomes with Enfortumab Vedotin in Patients with Histologic Subtypes of Advanced Urothelial Carcinoma: Analysis of the UNITE Study | Litcius